Tanvex BioPharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Stephen Lam

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Aug 07

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Mar 18

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Jan 19

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Nov 24

AMMINISTRATORE DELEGATO

Stephen Lam

less than a year

Mandato

Mr. Stephen Lam is Chief Executive Officer of Tanvex BioPharma, Inc. from September 5, 2024.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Lam	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Allen Chao	Founder & Honorary Chairman	no data	NT$111.00k	0.87% NT$ 97.5m
Wen Yeh	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Val Chen	VP of Finance Director of Ops. Mgmt.	no data	Nessun dato	Nessun dato
James Williamson	Accounting Officer	less than a year	Nessun dato	Nessun dato
Zheng Xia	Chief Technology Officer	9.8yrs	Nessun dato	Nessun dato
Linda Grillo	Director of Sales & Marketing	no data	Nessun dato	Nessun dato
Hsun-Chiang Hsieh	Secretary	no data	Nessun dato	Nessun dato

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di 6541 non è considerato esperto (durata media 0.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Allen Chao	Founder & Honorary Chairman	11.3yrs	NT$111.00k	0.87% NT$ 97.5m
David Hsia	Director	9.4yrs	Nessun dato	0.50% NT$ 55.6m
Lin-Cheng Chen	Chairman	less than a year	NT$5.00k	Nessun dato
Chi-Chuan Chen	Director	11yrs	NT$25.00k	0.010% NT$ 1.1m
Tamon Tseng	Director	11yrs	NT$25.00k	Nessun dato
Jin-Pau Tsai	Independent Director	9.4yrs	NT$682.00k	Nessun dato
Tay-Chang Wang	Independent Director	3.2yrs	NT$687.00k	Nessun dato
Jang-Yang Chang	Independent Director	2.3yrs	NT$570.00k	Nessun dato
Shang-Hsien Hsieh	Independent Director	less than a year	Nessun dato	Nessun dato
Chi-feng Chang	Independent Director	less than a year	Nessun dato	Nessun dato
Chun-Yen Chang	Independent Director	2.3yrs	NT$622.00k	Nessun dato

3.2yrs

Durata media

72yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6541 sono considerati esperti (durata media dell'incarico 6.1 anni).

Tanvex BioPharma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Recent updates

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

Second quarter 2024 earnings released: NT$2.31 loss per share (vs NT$3.89 loss in 2Q 2023)

Tanvex BioPharma, Inc. (TWSE:6541) agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. (TWSE:6472) and others for TWD 4.52 billion.

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Tanvex BioPharma, Inc. to Report Q2, 2024 Results on Aug 09, 2024

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

First quarter 2024 earnings released: NT$3.12 loss per share (vs NT$5.17 loss in 1Q 2023)

Tanvex BioPharma, Inc. to Report Q1, 2024 Results on May 07, 2024

Tanvex BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of TWD 1.44 billion.

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: NT$16.58 loss per share (vs NT$13.96 loss in FY 2022)

New major risk - Financial position

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer

Tanvex BioPharma, Inc. Announces Change of Chairman

Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer

Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer

Tanvex BioPharma, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Second quarter 2023 earnings released: NT$3.89 loss per share (vs NT$3.63 loss in 2Q 2022)

New minor risk - Shareholder dilution

Tanvex BioPharma, Inc. announced that it expects to receive TWD 220 million in funding

Less than half of directors are independent

Tanvex BioPharma, Inc. announced a financing transaction

Tanvex BioPharma, Inc. Appoints Jang-Yang Chang as Independent Director

Less than half of directors are independent

Tanvex BioPharma, Inc., Annual General Meeting, Jun 17, 2022

Tanvex BioPharma, Inc. Announces the Appointment of K. H. Lin as CFO and Accounting Officer, Effective from February 18, 2022

Price target decreased to NT$53.00

Price target increased to NT$67.00

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Tanvex BioPharma, Inc. Enters into A License Agreement with Amgen

New 90-day high: NT$44.95

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

New 90-day low: NT$36.55

New 90-day low: NT$37.15

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

New 90-day high: NT$45.95

Earnings miss expectations

New 90-day low - NT$37.00

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media